(0.20%) 5 142.00 points
(0.10%) 38 478 points
(0.34%) 17 907 points
(-0.82%) $83.16
(1.20%) $1.946
(-0.13%) $2 344.10
(-0.08%) $27.51
(2.36%) $943.90
(-0.16%) $0.933
(-0.12%) $11.01
(-0.32%) $0.798
(1.31%) $93.07
Live Chart Being Loaded With Signals
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China...
Stats | |
---|---|
Šios dienos apimtis | 18.07M |
Vidutinė apimtis | 5.10M |
Rinkos kapitalizacija | 63.00B |
EPS | HKD0 ( 2024-04-25 ) |
Last Dividend | HKD0.901 ( 2023-06-19 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 6.45 |
ATR14 | HKD0.0460 (0.23%) |
Tūris Koreliacija
SINOPHARM GROUP CO LTD Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
SINOPHARM GROUP CO LTD Koreliacija - Valiuta/Žaliavos
SINOPHARM GROUP CO LTD Finansinės ataskaitos
Annual | 2023 |
Pajamos: | HKD596.57B |
Bruto pelnas: | HKD48.51B (8.13 %) |
EPS: | HKD2.90 |
FY | 2023 |
Pajamos: | HKD596.57B |
Bruto pelnas: | HKD48.51B (8.13 %) |
EPS: | HKD2.90 |
FY | 2022 |
Pajamos: | HKD552.15B |
Bruto pelnas: | HKD47.43B (8.59 %) |
EPS: | HKD4.60 |
FY | 2021 |
Pajamos: | HKD521.05B |
Bruto pelnas: | HKD44.05B (8.45 %) |
EPS: | HKD2.49 |
Financial Reports:
No articles found.
SINOPHARM GROUP CO LTD Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.901 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0101 | 2010-04-29 |
Last Dividend | HKD0.901 | 2023-06-19 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 14 | -- |
Total Paid Out | HKD6.94 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.6 | -- |
Div. Sustainability Score | 9.69 | |
Div.Growth Potential Score | 3.37 | |
Div. Directional Score | 6.53 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3808.HK | Ex Dividend Junior | 2023-07-04 | Annually | 0 | 0.00% | |
1696.HK | Ex Dividend Junior | 2023-08-24 | Annually | 0 | 0.00% | |
0730.HK | Ex Dividend Junior | 2023-05-24 | Annually | 0 | 0.00% | |
2283.HK | Ex Dividend Knight | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
1270.HK | Ex Dividend Knight | 2023-05-16 | Annually | 0 | 0.00% | |
0323.HK | No Dividend Player | 2023-06-21 | Sporadic | 0 | 0.00% | |
6055.HK | Ex Dividend Knight | 2023-06-13 | Annually | 0 | 0.00% | |
1821.HK | Ex Dividend Junior | 2023-09-07 | Semi-Annually | 0 | 0.00% | |
0856.HK | Ex Dividend Junior | 2023-05-31 | Annually | 0 | 0.00% | |
0010.HK | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0155 | 1.500 | 9.69 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0358 | 1.200 | 8.81 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.194 | 1.500 | 8.96 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.395 | 0.800 | 8.03 | 6.42 | [1 - 3] |
quickRatioTTM | 1.034 | 0.800 | 8.63 | 6.90 | [0.8 - 2.5] |
cashRatioTTM | 0.264 | 1.500 | 9.64 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.188 | -1.500 | 6.87 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 20.69 | 1.000 | 3.45 | 3.45 | [3 - 30] |
operatingCashFlowPerShareTTM | 23.49 | 2.00 | 2.17 | 4.34 | [0 - 30] |
freeCashFlowPerShareTTM | 22.23 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.965 | -1.500 | 6.14 | -9.21 | [0 - 2.5] |
grossProfitMarginTTM | 0.0838 | 1.000 | -1.937 | -1.937 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0381 | 1.000 | -1.238 | -1.238 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.017 | 1.000 | 5.46 | 5.46 | [0.2 - 2] |
assetTurnoverTTM | 2.31 | 0.800 | 10.00 | 8.00 | [0.5 - 2] |
Total Score | 9.69 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 4.31 | 1.000 | 9.67 | 0 | [1 - 100] |
returnOnEquityTTM | 0.194 | 2.50 | 9.33 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 22.23 | 2.00 | 2.59 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.75 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 23.49 | 2.00 | 2.17 | 4.34 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0825 | 1.000 | -0.437 | 0 | [0.1 - 0.5] |
Total Score | 3.37 |
SINOPHARM GROUP CO LTD
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.